New drug IBI129 tested in humans for first time against Hard-to-Treat cancers
NCT ID NCT05991349
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested an experimental drug called IBI129 in 36 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find a safe dose and check for side effects. Researchers also looked for any signs that the drug might control tumor growth. Because this is a first-in-human study, the results are very preliminary and do not yet show whether IBI129 is an effective treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI129 (an experimental drug given by infusion every 3 weeks)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early, first-in-human study with only 36 participants. The drug may not shrink tumors or may cause side effects. Success in this small trial does not guarantee it will work for larger groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chris O'Brien Lifehouse
Camperdown, New South Wales, 2050, Australia
-
Hubei Cancer Hospital
Wuhan, Hubei, China
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
-
St George private Hospital
Kogarah, New South Wales, 2217, Australia
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
-
Tianjin Medical university cancer institute & Hospital
Tianjin, Tianjin Municipality, 300000, China
-
Wollongong Hospital
Wollongong, New South Wales, 2500, Australia